Whether it's perseverance or perseveration remains to be seen. But between the strong scientific evidence implicating amyloid beta in Alzheimer's disease (AD) and evidence of some progress in clinical trials, neither industry nor academia is willing to call it quits on pursuing amyloid beta as a target.